Fibroblast growth factor 2 is a key determinant of vascular sprouting during bovine luteal angiogenesis

Reproduction

Volumn 143, Issue 1, 2012, Pages 35-43

  Woad, Kathryn J ^a,b   Hunter, Morag G ^a   Mann, George E ^a   Laird, Mhairi ^a   Hammond, Amanda J ^a   Robinson, Robert S ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; FIBROBLAST GROWTH FACTOR 2; FIBRONECTIN; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN A; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; COW; ENDOTHELIUM CELL; FEMALE; IMMUNOHISTOCHEMISTRY; LUTEAL CELL; NONHUMAN; OVARY; PRIORITY JOURNAL;

ANIMALS; CATTLE; CELLS, CULTURED; CINNAMATES; CORPUS LUTEUM; ENDOTHELIAL CELLS; FEMALE; FIBROBLAST GROWTH FACTOR 2; LUTEAL CELLS; NEOVASCULARIZATION, PHYSIOLOGIC; PYRROLES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SIGNAL TRANSDUCTION; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

BOVINAE;

EID: 84855644172     PISSN: 14701626     EISSN: 17417899     Source Type: Journal    
DOI: 10.1530/REP-11-0277     Document Type: Article

References (53)

1. Affara M, Dunmore B, Savoie C, Imoto S, Tamada Y, Araki H, Charnock-Jones DS, Miyano S & Print C 2007 Understanding endothelial cell apoptosis: what can the transcriptome, glycome and proteome reveal? Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 362 1469-1487. (doi:10.1098/rstb.2007.2129)
2. Benjamin LE, Hemo I & Keshet E 1998 A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125 1591-1598. (Pubitemid 28256727)
3. Benjamin LE, Golijanin D, Itin A, Pode D & Keshet E 1999 Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. Journal of Clinical Investigation 103 159-165. (doi:10.1172/JCI5028)
4. Berisha B, Schams D, Kosmann M, Amselgruber W & Einspanier R 2000 Expression and tissue concentration of vascular endothelial growth factor, its receptors, and localization in the bovine corpus luteum during estrous cycle and pregnancy. Biology of Reproduction 63 1106-1114. (doi:10.1095/biolreprod63.4. 1106)
5. Bernard-Pierrot I, Ricol D, Cassidy A, Graham A, Elvin P, Caillault A, Lair S, Broet P, Thiery J-P & Radvanyi F 2004 Inhibition of human bladder tumour cell growth by fibroblast growth factor receptor 2b is independent of its kinase activity. Involvement of the carboxy-terminal region of the receptor. Oncogene 23 9201-9211. (doi:10.1038/sj.onc.1208150)
6. Brown HM, Robker RL & Russell DL 2010 Development and hormonal regulation of the ovarian lymphatic vasculature. Endocrinology 151 5446-5455. (doi:10.1210/en.2010-0629)
7. Cebe-Suarez S, Zehnder-Fjallman A & Ballmer-Hofer K 2006 The role of VEGF receptors in angiogenesis; complex partnerships. Cellular and Molecular Life Sciences 63 601-615. (doi:10.1007/s00018-005-5426-3)
8. Dickson SE, Bicknell R & Fraser HM 2001 Mid-luteal angiogenesis and function in the primate is dependent on vascular endothelial growth factor. Journal of Endocrinology 168 409-416. (doi:10.1677/joe.0.1680409)
9. Eilken HM & Adams RH 2010 Dynamics of endothelial cell behavior in sprouting angiogenesis. Current Opinion in Cell Biology 22 617-625. (doi:10.1016/j.ceb.2010.08.010)
10. Ferrara N 2004 Vascular endothelial growth factor: basic science and clinical progress. Endocrine Reviews 25 581-611. (doi:10.1210/er.2003-0027)
11. Ferrara N, Chen H, Davis-Smyth T, Gerber H-P, Nguyen T-N, Peers D, Chisholm V, Hillan KJ & Schwall RH 1998 Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nature Medicine 4 336-340. (doi:10.1038/nm0398-336)
12. Franco CA, Liebner S & Gerhardt H 2009 Vascular morphogenesis: a Wnt for every vessel? Current Opinion in Genetics & Development 19 476-483. (doi:10.1016/j.gde.2009.09.004)
13. Fraser HM, Dickson SE, Lunn SF, Wulff C, Morris KD, Carroll VA & Bicknell R 2000 Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor. Endocrinology 141 995-1000. (doi:10.1210/en.141.3.995)
14. Fraser HM, Wilson H, Morris KD, Swanston I & Wiegand SJ 2005 Vascular endothelial growth factor trap suppresses ovarian function at all stages of the luteal phase in the macaque. Journal of Clinical Endocrinology and Metabolism 90 5811-5818. (doi:10.1210/jc.2005-1199)
15. Fuks Z, Persaud RS, Alfieri A, McLoughlin M, Ehleiter D, Schwartz JL, Seddon AP, Cordon-Cardo C & Haimovitz-Friedman A 1994 Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Research 54 2582-2590. (Pubitemid 24173742)
16. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D et al. 2003 VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. Journal of Cell Biology 161 1163-1177. (doi:10.1083/jcb.200302047)
17. Gospodarowicz D, Massoglia S, Cheng J & Fujii DK 1986 Effect of fibroblast growth factor and lipoproteins on the proliferation of endothelial cells derived from bovine adrenal cortex, brain cortex, and corpus luteum capillaries. Journal of Cellular Physiology 127 121-136. (doi:10.1002/jcp. 1041270116)
18. Grand EK, Chase AJ, Heath C, Rahemtulla A & Cross NCP 2004 Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia 18 962-966. (doi:10.1038/sj.leu.2403347)
19. Gridley T 2007 Notch signaling in vascular development and physiology. Development 134 2709-2718. (doi:10.1242/dev.004184)
20. Guerra DM, Giometti IC, Price CA, Andrade PB, Castilho AC, Machado MF, Ripamonte P, Papa PC & Buratini J 2008 Expression of fibroblast growth factor receptors during development and regression of the bovine corpus luteum. Reproduction, Fertility and Development 20 659-664. (doi:10.1071/RD07114)
21. Hojo T, Al-Zi'abi MO, Komiyama J, Manabe N, Acosta TJ & Okuda K 2010 Expression and localization of cFLIP, an anti-apoptotic factor, in the bovine corpus luteum. Journal of Reproduction and Development 56 230-235. (doi:10.1262/jrd.09-185S)
22. Holderfield MT & Hughes CCW 2008 Crosstalk between vascular endothelial growth factor, Notch, and transforming growth factor-β in vascular morphogenesis. Circulation Research 102 637-652. (doi:10.1161/ CIRCRESAHA.107.167171)
23. Ireland JJ, Murphee RL & Coulson PB 1980 Accuracy of predicting stages of bovine estrous cycle by gross appearance of the corpus luteum. Journal of Dairy Science 63 155-160. (doi:10.3168/jds.S0022-0302(80)82901-8)
24. Karsan A, Yee E, Poirier GG, Zhou P, Craig R & Harlan JM 1997 Fibroblast growth factor-2 inhibits endothelial cell apoptosis by Bcl-2-dependent and independent mechanisms. American Journal of Pathology 151 1775-1784. (Pubitemid 27527940)
25. Katanasaka Y, Ida T, Asai T, Maeda N & Oku N 2008 Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes. International Journal of Pharmaceutics 360 219-224. (doi:10.1016/j.ijpharm.2008.04.046)
26. Larson SF, Butler WR & Currie WB 1997 Reduced fertility associated with low progesterone postbreeding and increased milk urea nitrogen in lactating cows. Journal of Dairy Science 80 1288-1295. (doi:10.3168/jds.S0022-0302(97) 76058-2)
27. Legg JA, Herbert JM, Clissold P & Bicknell R 2008 Slits and Round-abouts in cancer, tumour angiogenesis and endothelial cell migration. Angiogenesis 11 13-21. (doi:10.1007/s10456-008-9100-x)
28. Mann GE & Lamming GE 2001 Relationship between maternal endocrine environment, early embryo development and inhibition of the luteolytic mechanism in cows. Reproduction 121 175-180. (doi:10.1530/rep.0.1210175)
29. Masri FA, Xu W, Comhair SAA, Asosingh K, Koo M, Vasanji A, Drazba J, Anand-Apte B & Erzurum SC 2007 Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. American Journal of Physiology. Lung Cellular and Molecular Physiology 293 L548-L554. (doi:10.1152/ajplung.00428.2006)
30. Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK, Hubbard SR & Schlessinger J 1997 Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276 955-960. (doi:10.1126/science.276.5314.955)
31. Nicoli S, De Sena G & Presta M 2008 Fibroblast growth factor 2-induced angiogenesis in zebrafish: the zebrafish yolk membrane (ZFYM) angiogenesis assay. Journal of Cellular and Molecular Medicine 13 2061-2068. (doi:10.1111/j.1582-4934.2008.00432.x)
32. Numata Y, Terui T, Okuyama R, Hirasawa N, Sugiura Y, Miyoshi I, Watanabe T, Kuramasu A, Tagami H & Ohtsu H 2006 The accelerating effect of histamine on the cutaneous wound-healing process through the action of basic fibroblast growth factor. Journal of Investigative Dermatology 126 1403-1409. (doi:10.1038/sj.jid.5700253)
33. Olsson A-K, Dimberg A, Kreuger J & Claesson-Welsh L 2006 VEGF receptor signalling - in control of vascular function. Nature Reviews. Molecular Cell Biology 7 359-371. (doi:10.1038/nrm1911)
34. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G & Goldfarb M 1996 Receptor specificity of the fibroblast growth factor family. Journal of Biological Chemistry 271 15292-15297. (doi:10.1074/jbc.271. 25.15292)
35. Parsons-Wingerter P, Elliott KE, Clark JI & Farr AG 2000 Fibroblast growth factor-2 selectively stimulates angiogenesis of small vessels in arterial tree. Arteriosclerosis, Thrombosis, and Vascular Biology 20 1250-1256. (doi:10.1161/01.ATV.20.5.1250)
36. Pepper MS, Vassalli JD, Orci L & Montesano R 1993 Biphasic effect of transforming growth factor-b on in vitro angiogenesis. Experimental Cell Research 204 356-363. (doi:10.1006/excr.1993.1043)
37. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R & Rusnati M 2005 Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine & Growth Factor Reviews 16 159-178. (doi:10.1016/j.cytogfr.2005.01.004)
38. Robinson RS, Nicklin LT, Hammond AJ, Schams D, Hunter MG & Mann GE 2007 Fibroblast growth factor 2 is more dynamic than vascular endothelial growth factor A during the follicle-luteal transition in the cow. Biology of Reproduction 77 28-36. (doi:10.1095/biolreprod.106.055434)
39. Robinson RS, Hammond AJ, Mann GE & Hunter MG 2008 A novel physiological culture system that mimics luteal angiogenesis. Reproduction 135 405-413. (doi:10.1530/REP-07-0370)
40. Rousseau BT, Dubayle D, Sennlaub F, Jeanny J-C, Costet P, Bikfalvi A & Javerzat S 2000 Neural and angiogenic defects in eyes of transgenic mice expressing a dominant-negative FGF receptor in the pigmented cells. Experimental Eye Research 71 395-404. (doi:10.1006/exer.2000.0892)
41. Sawyer HR, Niswender KD, Braden TD & Niswender GD 1990 Nuclear changes in ovine luteal cells in response to PGF2[alpha]. Domestic Animal Endocrinology 7 229-237. (doi:10.1016/0739-7240(90)90029-Y)
42. Segura I, Serrano A, De Buitrago GG, Gonzalez MA, Abad JL, Claveria C, Gomez L, Bernad A, Martinez AC & Riese HH 2002 Inhibition of programmed cell death impairs in vitro vascular-like structure formation and reduces in vivo angiogenesis. FASEB Journal 16 833-841. (doi:10.1096/fj.01-0819com)
43. Stocco C, Telleria C & Gibori G 2007 The molecular control of corpus luteum formation, function, and regression. Endocrine Reviews 28 117-149. (doi:10.1210/er.2006-0022)
44. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A et al. 1996 Flk-1 as a target for tumor growth inhibition. Cancer Research 56 3540-3545. (Pubitemid 26251650)
45. Thomas M & Augustin H 2009 The role of the angiopoietins in vascular morphogenesis. Angiogenesis 12 125-137. (doi:10.1007/s10456-009-9147-3)
46. Woad KJ, Hammond AJ, Hunter M, Mann GE, Hunter MG & Robinson RS 2009 FGF2 is crucial for the development of bovine luteal endothelial networks in vitro. Reproduction 138 581-588. (doi:10.1530/REP-09-0030)
47. Wu J & Bresnick EH 2007 Glucocorticoid and growth factor synergism requirement for Notch4 chromatin domain activation. Molecular and Cellular Biology 27 2411-2422. (doi:10.1128/MCB.02152-06)
48. Wulff C, Wilson H, Rudge JS, Wiegand SJ, Lunn SF & Fraser HM 2001 Luteal angiogenesis: prevention and intervention by treatment with vascular endothelial growth factor trap(A40). Journal of Clinical Endocrinology and Metabolism 86 3377-3386. (doi:10.1210/jc.86.7.3377)
49. Xu F & Stouffer RL 2009 Existence of the lymphatic system in the primate corpus luteum. Lymphatic Research and Biology 7 159-168. (doi:10.1089/lrb.2009.0009)
50. Yamashita H, Kamada D, Shirasuna K, Matsui M, Shimizu T, Kida K, Berisha B, Schams D & Miyamoto A 2008 Effect of local neutralization of basic fibroblast growth factor or vascular endothelial growth factor by a specific antibody on the development of the corpus luteum in the cow. Molecular Reproduction and Development 75 1449-1456. (doi:10.1002/mrd.20878)
51. Yang S, Xin X, Zlot C, Ingle G, Fuh G, Li B, Moffat B, de Vos AM & Gerritsen ME 2001 Vascular endothelial cell growth factor-driven endothelial tube formation is mediated by vascular endothelial cell growth factor receptor-2, a kinase insert domain-containing receptor. Arteriosclerosis, Thrombosis, and Vascular Biology 21 1934-1940. (doi:10.1161/hq1201.099432)
52. Zimmermann RC, Hartman T, Bohlen P, Sauer MV & Kitajewski J 2001 Preovulatory treatment of mice with anti-VEGF receptor 2 antibody inhibits angiogenesis in corpora lutea. Microvascular Research 62 15-25. (doi:10.1006/mvre.2001.2312)
53. Zimrin AB, Pepper MS, McMahon GA, Nguyen F, Montesano R & Maciag T 1996 An antisense oligonucleotide to the notch ligand jagged enhances fibroblast growth factor-induced angiogenesis in vitro. Journal of Biological Chemistry 271 32499-32502. (doi:10.1074/jbc.271.51.32499)